Amneal Pharmaceuticals Inc (AMRX) Holdings Increased by Icon Advisers Inc. Co.
Icon Advisers Inc. Co. raised its holdings in shares of Amneal Pharmaceuticals Inc (NYSE:AMRX) by 11.3% during the 3rd quarter, HoldingsChannel reports. The fund owned 32,500 shares of the company’s stock after purchasing an additional 3,300 shares during the period. Icon Advisers Inc. Co.’s holdings in Amneal Pharmaceuticals were worth $721,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other institutional investors have also made changes to their positions in the business. SG Americas Securities LLC bought a new stake in shares of Amneal Pharmaceuticals in the 2nd quarter worth $120,000. Neuburgh Advisers LLC bought a new stake in shares of Amneal Pharmaceuticals in the 2nd quarter worth $123,000. Great West Life Assurance Co. Can bought a new stake in shares of Amneal Pharmaceuticals in the 2nd quarter worth $130,000. Sei Investments Co. bought a new stake in shares of Amneal Pharmaceuticals in the 2nd quarter worth $139,000. Finally, Riverhead Capital Management LLC bought a new stake in shares of Amneal Pharmaceuticals in the 2nd quarter worth $141,000. 31.84% of the stock is currently owned by hedge funds and other institutional investors.
In related news, SVP Nikita Shah sold 50,000 shares of Amneal Pharmaceuticals stock in a transaction on Tuesday, August 21st. The stock was sold at an average price of $23.46, for a total value of $1,173,000.00. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Bryan M. Reasons sold 11,698 shares of Amneal Pharmaceuticals stock in a transaction on Tuesday, August 21st. The stock was sold at an average price of $23.65, for a total value of $276,657.70. The disclosure for this sale can be found here. Insiders own 3.20% of the company’s stock.
Amneal Pharmaceuticals (NYSE:AMRX) last issued its earnings results on Wednesday, November 7th. The company reported $0.28 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.27 by $0.01. The business had revenue of $476.50 million for the quarter, compared to analysts’ expectations of $486.01 million. Amneal Pharmaceuticals had a positive return on equity of 6.62% and a negative net margin of 36.54%. Amneal Pharmaceuticals’s revenue was up 87.1% compared to the same quarter last year. As a group, research analysts expect that Amneal Pharmaceuticals Inc will post 0.91 EPS for the current fiscal year.
AMRX has been the topic of a number of research reports. B. Riley boosted their price objective on Amneal Pharmaceuticals from $26.00 to $28.00 and gave the stock a “buy” rating in a research note on Wednesday, August 22nd. Cantor Fitzgerald reissued a “buy” rating and issued a $35.00 price objective on shares of Amneal Pharmaceuticals in a research note on Thursday, August 9th. Zacks Investment Research raised Amneal Pharmaceuticals from a “hold” rating to a “buy” rating and set a $21.00 price objective on the stock in a research note on Saturday, July 14th. ValuEngine raised Amneal Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, August 3rd. Finally, Canaccord Genuity reissued a “hold” rating and issued a $21.00 price objective on shares of Amneal Pharmaceuticals in a research note on Monday, August 20th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and four have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and an average price target of $22.75.
TRADEMARK VIOLATION WARNING: This piece was originally reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this piece on another website, it was illegally stolen and reposted in violation of US & international trademark and copyright law. The correct version of this piece can be read at https://theolympiareport.com/2018/11/10/amneal-pharmaceuticals-inc-amrx-holdings-increased-by-icon-advisers-inc-co.html.
Amneal Pharmaceuticals Company Profile
Amneal Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes generic pharmaceutical products for various dosage forms and therapeutic areas. It operates through Generic and Specialty Pharma divisions. The company's generics portfolio includes approximately 200 product families marketed in various dosage forms, such as solid oral doses comprising tablets, capsules, and powders; liquids; sterile injectables; nasal sprays; inhalation and respiratory products; ophthalmics; films; transdermal patches; and topicals, as well as soft gel, complex molecule, and drug-device combinations.
Featured Story: What are the components of an earnings report?
Want to see what other hedge funds are holding AMRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amneal Pharmaceuticals Inc (NYSE:AMRX).
Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.